Pathophysiology and management of graft-versus-host disease in the era of reduced-intensity conditioning

Current Opinion in Oncology

Volumn 21, Issue SUPPL. 1, 2009, Pages

  Landfried, Karin ^a   Wolff, Daniel ^a   Holler, Ernst ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Antigen presenting cells; Graft versus host disease; Reduced intensity conditioning

Indexed keywords

ALEMTUZUMAB; CALCINEURIN INHIBITOR; CD4 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; ETANERCEPT; IMATINIB; INTERLEUKIN 1BETA; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT VERSUS HOST DISEASE; ADD ON THERAPY; ALLOIMMUNITY; ANTIGEN PRESENTING CELL; APOPTOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC GRAFT REJECTION; CHRONIC GRAFT VERSUS HOST DISEASE; DRUG MEGADOSE; GRAFT RECIPIENT; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INTESTINE GRAFT; LANGERHANS CELL; LOW DRUG DOSE; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; NONMYELOABLATIVE CONDITIONING; PATHOPHYSIOLOGY; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PUVA; REDUCED INTENSITY CONDITIONING; REGULATORY T LYMPHOCYTE; SHORT SURVEY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGEN-PRESENTING CELLS; ANTINEOPLASTIC AGENTS; GRAFT VS HOST DISEASE; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; PREDNISOLONE; RECEPTORS, TUMOR NECROSIS FACTOR; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING;

EID: 68049110517     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000357475.66035.d2     Document Type: Short Survey

References (15)

1. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant 1999; 5:347-356.
2. Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease. Lancet e-pub ahead of print 12 March 2009.
3. Johansson JE, Brune M, Ekman T. The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2001; 28:737-742.
4. Fukuda T, Hackman RC, Guthrie KA, et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 2003; 102:2777-2785.
5. Teshima T, Ordemann R, Reddy P, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002; 8:575-581.
6. Merad M, Hoffmann P, Ranheim E, et al. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med 2004; 10:510-517.
7. Collin MP, Hart DN, Jackson GH, et al. The fate of human Langerhans cells in hematopoietic stem cell transplantation. J Exp Med 2006; 203:27-33.
8. Turner BE, Kambouris ME, Sinfield L, et al. Reduced-intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease. Transplantation 2008; 86:968-976.
9. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11:945-956.
10. Sala-Torra O, Martin PJ, Storer B, et al. Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens. Bone Marrow Transplant 2008; 41:887-893.
11. Hockenbery DM, Cruickshank S, Rodell TC, et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 2007; 109: 4557-4563.
12. Holler E. The role of innate immunity in graft-versus-host disease and complications following allogeneic stem cell transplant. Biol Blood Marrow Transplant 2008; 15 (1 Suppl.):59-61.
13. Greinix HT, Knobler RM, Worel N, et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 2006; 91:405-408.
14. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371:1579-1586.
15. Weissinger EM, Schiffer E, Hertenstein B, et al. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2007; 109:5511-5519.